Sigyn Therapeutics, Inc. financial data

Symbol
SIGY on OTC
Location
9190 W Olympic Blvd # 263, Beverly Hills, CA
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 14, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 0.92 % -77.9%
Quick Ratio 1.25 % -25.7%
Debt-to-equity -103 % +5.64%
Return On Equity 62.1 % -41.6%
Return On Assets -2K % -74.1%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 1.61M shares
Common Stock, Shares, Outstanding 1.61M shares +13%
Entity Public Float 3.61M USD +93.9%
Common Stock, Value, Issued 161 USD +13.4%
Weighted Average Number of Shares Outstanding, Basic 1.61M shares +26.5%
Weighted Average Number of Shares Outstanding, Diluted 1.61M shares +26.5%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 140K USD -84.3%
General and Administrative Expense 1.7M USD -8.66%
Operating Income (Loss) -1.88M USD +31.8%
Nonoperating Income (Expense) -1.34M USD -8.58%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -3.22M USD +19.3%
Net Income (Loss) Attributable to Parent -3.22M USD +19.3%
Earnings Per Share, Basic -1 USD/shares +38.7%
Earnings Per Share, Diluted -1 USD/shares +38.7%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 85.6K USD -48.1%
Inventory, Net 50K USD 0%
Other Assets, Current 1.3K USD -97%
Assets, Current 85.6K USD -68.2%
Property, Plant and Equipment, Net 8.32K USD -39.6%
Operating Lease, Right-of-Use Asset 97.2K USD -37.1%
Other Assets, Noncurrent 50K USD +141%
Assets 136K USD -68.3%
Accounts Payable, Current 774K USD +26.5%
Liabilities, Current 3.99M USD -6.69%
Operating Lease, Liability, Noncurrent 37.5K USD -65.8%
Liabilities 6.05M USD +39.1%
Retained Earnings (Accumulated Deficit) -17.4M USD -22.7%
Stockholders' Equity Attributable to Parent -5.92M USD -50.9%
Liabilities and Equity 136K USD -68.3%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -294K USD -25%
Net Cash Provided by (Used in) Financing Activities 295K USD +15%
Common Stock, Shares Authorized 100M shares -90%
Common Stock, Shares, Issued 1.61M shares +13%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 751 USD -96.4%
Deferred Tax Assets, Valuation Allowance 3.96M USD +30.9%
Operating Lease, Liability 110K USD -36.5%
Depreciation 2.72K USD -53.5%
Lessee, Operating Lease, Liability, to be Paid 114K USD -40.5%
Operating Lease, Liability, Current 72.3K USD +14.3%
Lessee, Operating Lease, Liability, to be Paid, Year Two 54.2K USD -31.8%
Lessee, Operating Lease, Liability, to be Paid, Year One 59.9K USD +3%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 4.36K USD -76.9%
Lessee, Operating Lease, Liability, to be Paid, Year Three 54.2K USD +0%
Deferred Tax Assets, Operating Loss Carryforwards 4.01M USD +31%
Preferred Stock, Shares Issued 1.15 shares
Preferred Stock, Shares Authorized 10M shares 0%
Operating Lease, Payments 19.5K USD +3%
Additional Paid in Capital 11.5M USD +12%
Preferred Stock, Shares Outstanding 1.15 shares
Amortization of Intangible Assets 2.1K USD -41.7%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%